Jakavi or Jakafi (generic name: ruxolitinib) is a prescription drug manufactured by Novartis approved for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis , post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar tissue.
It comes in tablet form & pack size of 56 tablets ( 4 strips of 14 tablets). Available in dosage of is 5 mg, 15 mg & 20 mg.
Note: Also known as Jakafi in other parts of the world
Patients may suffer debilitating symptoms including fever, extreme fatigue, intractable pruritus (itchiness), night sweats, weight loss, bone or muscle pain, poor quality of life and shortened survival.